Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-dopa Treatment in CTNNB1 Syndrome
NCT07614126Recruiting
- Sponsor
- CHU Montpellier
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of levodopa in CTNNB1 syndrome (CTNNB1), sponsored by CHU Montpellier. Primary endpoint: Assessment of motor skills at 6 months. Started Apr 2026; status: recruiting.
02
Drugs
levodopa
03
Conditions
CTNNB1 syndrome (CTNNB1)
Beyond the preview
Go deeper on NCT07614126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614126.